[Lipid-lowering drugs. Therapeutics and adverse effects].
D001161:Arteriosclerosis / Q000517:prevention & control*; D002648:Child; D002769:Cholelithiasis / Q000139:chemically induced; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002994:Clofibrate / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003084:Colestipol / Q000627:therapeutic use; D003918:Dextrothyroxine / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000037:antagonists & inhibitors; D009539:Nicotinic Acids / Q000627:therapeutic use; D010642:Phenoxyacetates / Q000627:therapeutic use; D012855:Sitosterols / Q000627:therapeutic use
D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D009539:Nicotinic Acids; D010642:Phenoxyacetates; D012855:Sitosterols; D002792:Cholestyramine Resin; D003918:Dextrothyroxine; D002994:Clofibrate; D003084:Colestipol
Lipidsenkende Medikamente. Therapieeffekt und Nebenwirkungen.